{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:28:05Z","timestamp":1788488885693,"version":"build-2803163510"},"reference-count":324,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000291","name":"Kidney Research UK","doi-asserted-by":"publisher","award":["SF_001_20181122"],"award-info":[{"award-number":["SF_001_20181122"]}],"id":[{"id":"10.13039\/501100000291","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["139"],"award-info":[{"award-number":["139"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/T002263\/1"],"award-info":[{"award-number":["MR\/T002263\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009270","name":"Invention for Innovation","doi-asserted-by":"publisher","award":["II-LA-0712-20003"],"award-info":[{"award-number":["II-LA-0712-20003"]}],"id":[{"id":"10.13039\/501100009270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012068","name":"Health and Care Research Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012068","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115974"],"award-info":[{"award-number":["115974"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008664","name":"Juvenile Diabetes Research Foundation United Kingdom","doi-asserted-by":"publisher","award":["RP44\/2014"],"award-info":[{"award-number":["RP44\/2014"]}],"id":[{"id":"10.13039\/100008664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.addr.2021.114045","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T10:48:29Z","timestamp":1636454909000},"page":"114045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["MicroRNAs and their delivery in diabetic fibrosis"],"prefix":"10.1016","volume":"182","author":[{"given":"Alexa","family":"Wonnacott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Denby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.M.","family":"Coward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2021.114045_b0005","doi-asserted-by":"crossref","first-page":"C216","DOI":"10.1152\/ajpcell.00328.2012","article-title":"Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis","volume":"304","author":"Zeisberg","year":"2013","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.addr.2021.114045_b0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41586-020-2941-1","article-title":"Decoding myofibroblast origins in human kidney fibrosis","volume":"589","author":"Kuppe","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.114045_b0015","first-page":"1429","article-title":"Single-cell ATAC sequencing analysis: From data preprocessing to hypothesis generation, Comput Struct","volume":"18","author":"Baek","year":"2020","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.addr.2021.114045_b0020","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1373\/clinchem.2014.237016","article-title":"The Sequence of the Human Genome","volume":"61","author":"Venter","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.addr.2021.114045_b0025","doi-asserted-by":"crossref","first-page":"baw153","DOI":"10.1093\/database\/baw153","article-title":"GeneBase 1.1: a tool to summarize data from NCBI gene datasets and its application to an update of human gene statistics","author":"Piovesan","year":"2016","journal-title":"Database"},{"key":"10.1016\/j.addr.2021.114045_b0030","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nature03001","article-title":"Finishing the euchromatic sequence of the human genome","volume":"431","author":"I.H.G.S. Consortium","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.114045_b0035","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13059-018-1590-2","article-title":"CHESS: a new human gene catalog curated from thousands of large-scale RNA sequencing experiments reveals extensive transcriptional noise","volume":"19","author":"Pertea","year":"2018","journal-title":"Genome Biol."},{"key":"10.1016\/j.addr.2021.114045_b0040","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41588-018-0062-7","article-title":"The human noncoding genome defined by genetic diversity","volume":"50","author":"di Iulio","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2021.114045_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101041","article-title":"Regulation of inflammation in diabetes: From genetics to epigenomics evidence","volume":"41","author":"Diedisheim","year":"2020","journal-title":"Mol. Metab."},{"key":"10.1016\/j.addr.2021.114045_b0050","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1101\/gr.254904.119","article-title":"A comparison of gene expression and DNA methylation patterns across tissues and species","volume":"30","author":"Blake","year":"2020","journal-title":"Genome Res."},{"key":"10.1016\/j.addr.2021.114045_b0055","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-020-2449-8","article-title":"Perspectives on ENCODE","volume":"583","author":"Snyder","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.114045_b0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41571-019-0273-6","article-title":"A systems approach to clinical oncology uses deep phenotyping to deliver personalized care","volume":"17","author":"Yurkovich","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2021.114045_b0065","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/nature14962","article-title":"The UK10K project identifies rare variants in health and disease","volume":"526","author":"Walter","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.114045_b0070","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1093\/hmg\/ddy115","article-title":"Deep learning of genomic variation and regulatory network data","volume":"27","author":"Telenti","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2021.114045_b0075","doi-asserted-by":"crossref","first-page":"D212","DOI":"10.1093\/nar\/gkaa921","article-title":"RNAcentral 2021: secondary structure integration, improved sequence search and new member databases","volume":"49","author":"R. Consortium","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2021.114045_b0080","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.tree.2008.06.005","article-title":"Origins and evolution of eukaryotic RNA interference","volume":"23","author":"Shabalina","year":"2008","journal-title":"Trends Ecol. Evol."},{"key":"10.1016\/j.addr.2021.114045_b0085","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2021.114045_b0090","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrg3965","article-title":"Towards a molecular understanding of microRNA-mediated gene silencing","volume":"16","author":"Jonas","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2021.114045_b0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan MicroRNAs","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.addr.2021.114045_b0100","doi-asserted-by":"crossref","first-page":"eaav1741","DOI":"10.1126\/science.aav1741","article-title":"The biochemical basis of microRNA targeting efficacy","volume":"366","author":"McGeary","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.addr.2021.114045_b0105","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.molcel.2014.04.016","article-title":"quantitative assessment of the sequence and structural binding specificity of RNA binding proteins","volume":"54","author":"Lambert","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.addr.2021.114045_b0110","doi-asserted-by":"crossref","first-page":"17764","DOI":"10.1073\/pnas.1920404117","article-title":"The biochemical basis for the cooperative action of microRNAs","volume":"117","author":"Briskin","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2021.114045_b0115","doi-asserted-by":"crossref","first-page":"12960","DOI":"10.1038\/s41598-020-69791-5","article-title":"Dynamical gene regulatory networks are tuned by transcriptional autoregulation with microRNA feedback","volume":"10","author":"Minchington","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.114045_b0120","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/path.4119","article-title":"MicroRNAs, transforming growth factor beta-1, and tissue fibrosis","volume":"229","author":"Bowen","year":"2013","journal-title":"J. Pathol."},{"key":"10.1016\/j.addr.2021.114045_b0125","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1007\/s00204-016-1815-7","article-title":"MicroRNA epigenetic signatures in human disease","volume":"90","author":"Pileti\u010d","year":"2016","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.addr.2021.114045_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.108763","article-title":"Roles of microRNAs in chronic pediatric diseases and their use as potential biomarkers: A review","volume":"699","author":"Paul","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.addr.2021.114045_b0135","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2337\/db15-0389","article-title":"Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes","volume":"65","author":"Zampetaki","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b0140","doi-asserted-by":"crossref","first-page":"e1255","DOI":"10.1111\/aos.14845","article-title":"MicroRNAs and the HIF\/VEGF axis in ocular neovascular diseases","volume":"99","author":"Plastino","year":"2021","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.addr.2021.114045_b0145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1210\/er.2016-1122","article-title":"Emerging Roles for MicroRNAs in Diabetic Microvascular Disease: Novel Targets for Therapy","volume":"38","author":"Zhang","year":"2017","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.addr.2021.114045_b0150","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2021.114045_b0155","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.ygeno.2020.10.024","article-title":"Non-coding RNAs: The key detectors and regulators in cardiovascular disease","volume":"113","author":"Zhu","year":"2021","journal-title":"Genomics"},{"key":"10.1016\/j.addr.2021.114045_b0160","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3389\/fphys.2018.01256","article-title":"Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders","volume":"9","author":"Turchinovich","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.addr.2021.114045_b0165","article-title":"miRNA Dysregulation in the Development of Non-Alcoholic Fatty Liver Disease and the Related Disorders Type 2 Diabetes Mellitus and Cardiovascular Disease","volume":"7","author":"L\u00f3pez-Pastor","year":"2020","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.addr.2021.114045_b0170","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.3390\/ijms21124370","article-title":"MicroRNA and ROS Crosstalk in Cardiac and Pulmonary Diseases","volume":"21","author":"Climent","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2021.114045_b0175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrneph.2014.202","article-title":"MicroRNAs in kidney physiology and disease","volume":"11","author":"Trionfini","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b0180","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/nyas.12758","article-title":"MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets","volume":"1353","author":"Kato","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.addr.2021.114045_b0185","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.2337\/db15-0116","article-title":"Circulating TGF-\u03b21-Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes","volume":"64","author":"Pezzolesi","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b0190","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11892-016-0724-8","article-title":"MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy","volume":"16","author":"Simpson","year":"2016","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.addr.2021.114045_b0195","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MNH.0000000000000356","article-title":"MicroRNAs as biomarkers in chronic kidney disease","volume":"26","author":"Wonnacott","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.addr.2021.114045_b0200","first-page":"30","article-title":"Biogenesis, Stabilization, and Transport of microRNAs in Kidney Health and Disease","volume":"4","author":"Thomas","year":"2018","journal-title":"Noncoding RNA"},{"key":"10.1016\/j.addr.2021.114045_b0205","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41576-020-00309-5","article-title":"The roles of microRNAs in mouse development","volume":"22","author":"DeVeale","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2021.114045_b0210","doi-asserted-by":"crossref","first-page":"12864","DOI":"10.1038\/ncomms12864","article-title":"An endoplasmic reticulum stress-regulated lncRNA hosting a microRNA megacluster induces early features of diabetic nephropathy","volume":"7","author":"Kato","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2021.114045_b0215","doi-asserted-by":"crossref","first-page":"10900","DOI":"10.1038\/s41598-019-47504-x","article-title":"Differential Expression of Urinary Exosomal MicroRNAs miR-21-5p and miR-30b-5p in Individuals with Diabetic Kidney Disease","volume":"9","author":"Zang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.114045_b0220","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ymthe.2016.08.001","article-title":"Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice","volume":"25","author":"K\u00f6lling","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2021.114045_b0225","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1681\/ASN.2013121274","article-title":"MicroRNA-21 in glomerular injury","volume":"26","author":"Lai","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b0230","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1681\/ASN.2013050527","article-title":"MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction","volume":"25","author":"Lin","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.586895","article-title":"Knockdown of LncRNA-H19 Ameliorates Kidney Fibrosis in Diabetic Mice by Suppressing miR-29a-Mediated EndMT","volume":"11","author":"Shi","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2021.114045_b0240","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"B.D.W. Group","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2021.114045_b0245","first-page":"151","article-title":"Stabilization of Urinary MicroRNAs by Association with Exosomes and Argonaute 2 Protein, Non-Coding","volume":"1","author":"Beltrami","year":"2015","journal-title":"RNA"},{"key":"10.1016\/j.addr.2021.114045_b0250","doi-asserted-by":"crossref","first-page":"10136","DOI":"10.1038\/s41598-019-46585-y","article-title":"Neutrophil-derived miR-223 as local biomarker of bacterial peritonitis","volume":"9","author":"Brook","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.114045_b0255","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/ctr.12679","article-title":"MicroRNA-21 (miR-21) expression in hypothermic machine perfusate may be predictive of early outcomes in kidney transplantation","volume":"30","author":"Khalid","year":"2016","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.addr.2021.114045_b0260","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-1-4939-9841-8_17","article-title":"Assessment of Urinary MicroRNAs by Quantitative Polymerase Chain Reaction in Diabetic Nephropathy Patients","volume":"2067","author":"Newbury","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2021.114045_b0265","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.ajpath.2018.06.006","article-title":"Association of Elevated Urinary miR-126, miR-155, and miR-29b with Diabetic Kidney Disease","volume":"188","author":"Beltrami","year":"2018","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.addr.2021.114045_b0270","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.ajpath.2017.03.007","article-title":"miR-21 Promotes Fibrogenesis in Peritoneal Dialysis","volume":"187","author":"Lopez-Anton","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.addr.2021.114045_b0275","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1038\/s41598-019-38642-3","article-title":"A urinary microRNA panel that is an early predictive biomarker of delayed graft function following kidney transplantation","volume":"9","author":"Khalid","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.114045_b0280","doi-asserted-by":"crossref","first-page":"9862","DOI":"10.1038\/s41598-021-89195-3","article-title":"Determination of a microRNA signature of protective kidney ischemic preconditioning originating from proximal tubules","volume":"11","author":"Khalid","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.114045_b0285","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.coph.2016.02.001","article-title":"Targeting non-coding RNA for the therapy of renal disease","volume":"27","author":"Denby","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.addr.2021.114045_b0290","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.kint.2020.02.008","article-title":"Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease","volume":"98","author":"Magayr","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2021.114045_b0295","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.addr.2020.04.004","article-title":"Extracellular vesicles as drug delivery systems: Why and how?","volume":"159","author":"Elsharkasy","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.114045_b0300","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41581-019-0248-y","article-title":"Targeting the progression of chronic kidney disease","volume":"16","author":"Ruiz-Ortega","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.587689","article-title":"Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAs","volume":"11","author":"Sakuma","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2021.114045_b0310","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2337\/diabetes.48.5.937","article-title":"Hyperglycemia and cardiovascular disease in type 2 diabetes","volume":"48","author":"Laakso","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b0315","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.114045_b0320","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.addr.2021.114045_b0325","doi-asserted-by":"crossref","unstructured":"J.B. Buse, D.J. Wexler, A. Tsapas, P. Rossing, G. Mingrone, C. Mathieu, D.A. D'Alessio, M.J. Davies, 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care 43 (2020) 487\u2013493.","DOI":"10.2337\/dci19-0066"},{"key":"10.1016\/j.addr.2021.114045_b0330","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.2337\/dc18-1226","article-title":"The Economic Burden of Elevated Blood Glucose Levels in 2017: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes","volume":"42","author":"Dall","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2021.114045_b0340","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2337\/diacare.27.3.813","article-title":"Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes","volume":"27","author":"Pickup","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2021.114045_b0345","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1464-5491.2003.01030.x","article-title":"Type 2 diabetes mellitus: a disease of the innate immune system? An update","volume":"21","author":"Crook","year":"2004","journal-title":"Diabet. Med."},{"key":"10.1016\/j.addr.2021.114045_b0350","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-4684-8508-0_8","article-title":"Biochemistry of the basement membrane in diabetes mellitus","volume":"124","author":"Brownlee","year":"1979","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.addr.2021.114045_b0355","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/path.1439","article-title":"Microvascular basement membranes in diabetes mellitus","volume":"200","author":"Tsilibary","year":"2003","journal-title":"J. Pathol."},{"key":"10.1016\/j.addr.2021.114045_b0360","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/112067210501500312","article-title":"Immunohistochemical study of extracellular matrix components in epiretinal membranes of vitreoproliferative retinopathy and proliferative diabetic retinopathy","volume":"15","author":"Ioachim","year":"2005","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.addr.2021.114045_b0365","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.exer.2015.04.004","article-title":"Retinal fibrosis in diabetic retinopathy","volume":"142","author":"Roy","year":"2016","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2021.114045_b0370","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3129\/i08-007","article-title":"Combined rhegmatogenous and traction retinal detachment in proliferative diabetic retinopathy: clinical manifestations and surgical outcome","volume":"43","author":"Yang","year":"2008","journal-title":"Can. J. Ophthalmol."},{"key":"10.1016\/j.addr.2021.114045_b0375","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4103\/0301-4738.100542","article-title":"The worldwide epidemic of diabetic retinopathy","volume":"60","author":"Zheng","year":"2012","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.addr.2021.114045_b0380","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/0002-8703(80)90379-8","article-title":"Clinical and morphological features of human hypertensive-diabetic cardiomyopathy","volume":"99","author":"Factor","year":"1980","journal-title":"Am. Heart J."},{"key":"10.1016\/j.addr.2021.114045_b0385","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/jcp.46.1.32","article-title":"Collagen remodelling in myocardia of patients with diabetes","volume":"46","author":"Shimizu","year":"1993","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.addr.2021.114045_b0390","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1172\/JCI108843","article-title":"Evidence for cardiomyopathy in familial diabetes mellitus","volume":"60","author":"Regan","year":"1977","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2021.114045_b0395","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2021.114045_b0400","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2021.114045_b0405","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2337\/dc06-1539","article-title":"Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease","volume":"30","author":"Tolman","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2021.114045_b0410","first-page":"S1","article-title":"Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"10","author":"Amiri Dash Atan","year":"2017","journal-title":"Gastroenterol. Hepatol. Bed. Bench"},{"key":"10.1016\/j.addr.2021.114045_b0415","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1111\/jgh.14734","article-title":"Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease","volume":"34","author":"Tada","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2021.114045_b0420","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/s41598-019-39112-6","article-title":"Transcriptional regulation of Hepatic Stellate Cell activation in NASH","volume":"9","author":"Marcher","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.114045_b0425","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2021.114045_b0430","first-page":"580","article-title":"Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States","author":"Younossi","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.addr.2021.114045_b0435","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1378\/chest.123.6.2007","article-title":"Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis","volume":"123","author":"Enomoto","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.addr.2021.114045_b0440","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.rmed.2009.08.013","article-title":"Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study","volume":"104","author":"Garc\u00eda-Sancho Figueroa","year":"2010","journal-title":"Respir. Med."},{"key":"10.1016\/j.addr.2021.114045_b0445","doi-asserted-by":"crossref","first-page":"11920","DOI":"10.1038\/s41598-018-30449-y","article-title":"Diabetes induces fibrotic changes in the lung through the activation of TGF-\u03b2 signaling pathways","volume":"8","author":"Talakatta","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.114045_b0450","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11154-019-09516-w","article-title":"Diabetic lung disease: fact or fiction?","volume":"20","author":"Kolahian","year":"2019","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.addr.2021.114045_b0455","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/bmj.38070.450891.FE","article-title":"Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study","volume":"328","author":"Hovind","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.addr.2021.114045_b0460","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003013","article-title":"Risk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-Analysis","volume":"95","author":"Tsai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.addr.2021.114045_b0465","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.addr.2021.114045_b0470","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.2215\/CJN.01120211","article-title":"Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus","volume":"6","author":"Thakar","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b0475","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3389\/fendo.2018.00693","article-title":"The Evolving Importance of Insulin Signaling in Podocyte Health and Disease","volume":"9","author":"Lay","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.addr.2021.114045_b0480","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.dsx.2018.11.014","article-title":"Albuminuric and non-albuminuric patterns of chronic kidney disease in type 2 diabetes","volume":"13","author":"Klimontov","year":"2019","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.addr.2021.114045_b0485","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.kint.2020.02.010","article-title":"Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference","volume":"97","author":"Levey","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2021.114045_b0490","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1186\/1755-1536-5-S1-S14","article-title":"Fibrosis in the kidney: is a problem shared a problem halved?","volume":"5","author":"Hewitson","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"Suppl 2","key":"10.1016\/j.addr.2021.114045_b0495","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ajt.15274","article-title":"OPTN\/SRTR 2017 Annual Data Report: Kidney","volume":"19","author":"Hart","year":"2019","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.addr.2021.114045_b0505","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/ndt\/gfr518","article-title":"Are the high mortality rates in dialysis patients mainly due to cardiovascular causes?","volume":"27","author":"Krediet","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.addr.2021.114045_b0510","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/ndt\/gfu216","article-title":"European Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care","volume":"30","author":"Abramowicz","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.addr.2021.114045_b0515","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.114045_b0520","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"I.i.P.w.T.D.a.M.S. Group, The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.114045_b0525","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0272-6386(99)70037-5","article-title":"Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients","volume":"34","author":"Sharma","year":"1999","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.addr.2021.114045_b0530","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/hy09t1.094234","article-title":"Angiotensin II and renal fibrosis","volume":"38","author":"Mezzano","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.addr.2021.114045_b0535","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejheart.2004.04.013","article-title":"The clinical implications of aldosterone escape in congestive heart failure","volume":"6","author":"Struthers","year":"2004","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.addr.2021.114045_b0540","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.114045_b0545","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.114045_b0550","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.114045_b0555","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1681\/ASN.2006050445","article-title":"Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"18","author":"Eijkelkamp","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b0560","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.114045_b0565","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/ndt\/gfaa234","article-title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics","volume":"35","author":"Wheeler","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.addr.2021.114045_b0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165703","article-title":"Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes","volume":"11","author":"Shin","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.114045_b0575","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/dme.13107","article-title":"Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes","volume":"33","author":"Wang","year":"2016","journal-title":"Diabet. Med."},{"key":"10.1016\/j.addr.2021.114045_b0580","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.kint.2018.04.025","article-title":"Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice","volume":"94","author":"Tanaka","year":"2018","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2021.114045_b0585","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.addr.2021.114045_b0590","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.addr.2021.114045_b0595","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000505144","article-title":"Renal Anti-Fibrotic Effect of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension","volume":"51","author":"Castoldi","year":"2020","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b0600","doi-asserted-by":"crossref","first-page":"F1017","DOI":"10.1152\/ajprenal.00021.2020","article-title":"Reduced O-GlcNAcylation and tubular hypoxia contribute to the antifibrotic effect of SGLT2 inhibitor dapagliflozin in the diabetic kidney","volume":"318","author":"Hodrea","year":"2020","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.addr.2021.114045_b0605","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.addr.2021.114045_b0610","first-page":"2098","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Rajagopalan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.114045_b0615","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1111\/dom.13847","article-title":"GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials","volume":"21","author":"Giugliano","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.addr.2021.114045_b0620","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbrc.2017.11.076","article-title":"Recombinant human GLP-1(rhGLP-1) alleviating renal tubulointestitial injury in diabetic STZ-induced rats","volume":"495","author":"Yin","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2021.114045_b0625","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.metabol.2012.03.002","article-title":"GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases","volume":"61","author":"Hendarto","year":"2012","journal-title":"Metabolism"},{"key":"10.1016\/j.addr.2021.114045_b0630","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and Renal Outcomes in Type 2 Diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.114045_b0635","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ackd.2018.01.002","article-title":"New Glucose-Lowering Agents for Diabetic Kidney Disease","volume":"25","author":"de Vos","year":"2018","journal-title":"Adv. Chronic Kidney Dis."},{"key":"10.1016\/j.addr.2021.114045_b0640","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.addr.2021.114045_b0645","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.2337\/db17-1212","article-title":"Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy","volume":"67","author":"Moellmann","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b0650","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2337\/db13-1029","article-title":"Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen","volume":"63","author":"Kanasaki","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b0655","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.2337\/dc13-0323","article-title":"Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction","volume":"36","author":"Groop","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2021.114045_b0660","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.addr.2021.114045_b0665","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3390\/jcm4061171","article-title":"Endothelin Blockade in Diabetic Kidney Disease","volume":"4","author":"Anguiano","year":"2015","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2021.114045_b0670","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1172\/JCI119297","article-title":"Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension","volume":"99","author":"Hocher","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2021.114045_b0675","doi-asserted-by":"crossref","first-page":"11003","DOI":"10.1074\/jbc.M110.190793","article-title":"Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop","volume":"286","author":"Simonson","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2021.114045_b0680","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b0685","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.114045_b0690","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2021.114045_b0695","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus","volume":"147","author":"Guo","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.addr.2021.114045_b0700","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1681\/ASN.2005111196","article-title":"Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats","volume":"17","author":"Han","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b0705","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.114045_b0710","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0272-6386(00)70189-2","article-title":"Advanced glycation end products: a Nephrologist's perspective","volume":"35","author":"Raj","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.addr.2021.114045_b0715","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/sj.ki.5001578","article-title":"Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db\/db mice","volume":"70","author":"Zheng","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2021.114045_b0720","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000108104","article-title":"Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy","volume":"27","author":"Williams","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b0725","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1681\/ASN.2011030272","article-title":"Pyridorin in type 2 diabetic nephropathy","volume":"23","author":"Lewis","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b0730","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/jcm9020458","article-title":"Inflammatory Targets in Diabetic Nephropathy","volume":"9","author":"Donate-Correa","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2021.114045_b0735","doi-asserted-by":"crossref","first-page":"F716","DOI":"10.1152\/ajprenal.00314.2016","article-title":"Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets","volume":"312","author":"Pichler","year":"2017","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.addr.2021.114045_b0740","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.addr.2021.114045_b0745","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.114045_b0750","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.114045_b0755","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cardfail.2014.10.001","article-title":"Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl","volume":"20","author":"Chin","year":"2014","journal-title":"J. Card Fail"},{"key":"10.1016\/j.addr.2021.114045_b0760","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2021.114045_b0765","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1523-1755.1998.00962.x","article-title":"Pirfenidone improves renal function and fibrosis in the post-obstructed kidney","volume":"54","author":"Shimizu","year":"1998","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2021.114045_b0770","first-page":"S239","article-title":"Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy","volume":"63","author":"Shimizu","year":"1997","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.addr.2021.114045_b0775","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/506041","article-title":"TGF-Beta Blockade Increases Renal Inflammation Caused by the C-Terminal Module of the CCN2","volume":"2015","author":"Rodrigues-D\u00edez","year":"2015","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.addr.2021.114045_b0780","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1681\/ASN.2010101049","article-title":"Pirfenidone for diabetic nephropathy","volume":"22","author":"Sharma","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b0785","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1681\/ASN.2015111230","article-title":"Anti-TGF-\u03b21 Antibody Therapy in Patients with Diabetic Nephropathy","volume":"28","author":"Voelker","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b0790","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.2014010012","article-title":"Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial","volume":"26","author":"Navarro-Gonz\u00e1lez","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b0795","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1101\/gr.082701.108","article-title":"Most mammalian mRNAs are conserved targets of microRNAs","volume":"19","author":"Friedman","year":"2009","journal-title":"Genome Res."},{"key":"10.1016\/j.addr.2021.114045_b0800","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/dmrr.291","article-title":"Insulin resistance in type 1 diabetes","volume":"18","author":"Greenbaum","year":"2002","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.addr.2021.114045_b0805","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJM198607243150404","article-title":"Natural course of insulin resistance in type I diabetes","volume":"315","author":"Yki-J\u00e4rvinen","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.114045_b0810","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Banting lecture 1988. Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b0815","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1046\/j.1523-1755.2002.00507.x","article-title":"Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study","volume":"62","author":"Orchard","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2021.114045_b0820","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.2337\/diacare.27.11.2661","article-title":"Different patterns of insulin resistance in relatives of type 1 diabetic patients with retinopathy or nephropathy: the Genesis France-Belgium Study","volume":"27","author":"Hadjadj","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2021.114045_b0825","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/BF00284458","article-title":"Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study","volume":"25","author":"Andersen","year":"1983","journal-title":"Diabetologia"},{"key":"10.1016\/j.addr.2021.114045_b0830","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2337\/dc10-1718","article-title":"Association between insulin resistance and development of microalbuminuria in type 2 diabetes: a prospective cohort study","volume":"34","author":"Hsu","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.addr.2021.114045_b0835","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","article-title":"Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study","volume":"7","author":"Zaharia","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.addr.2021.114045_b0840","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nature10112","article-title":"MicroRNAs 103 and 107 regulate insulin sensitivity","volume":"474","author":"Trajkovski","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.114045_b0845","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.febslet.2014.05.011","article-title":"Induction of miR-29a by saturated fatty acids impairs insulin signaling and glucose uptake through translational repression of IRS-1 in myocytes","volume":"588","author":"Yang","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2021.114045_b0850","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2337\/db17-0141","article-title":"Altered miR-29 Expression in Type 2 Diabetes Influences Glucose and Lipid Metabolism in Skeletal Muscle","volume":"66","author":"Massart","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b0855","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/CIRCRESAHA.115.308166","article-title":"MicroRNA-181b Improves Glucose Homeostasis and Insulin Sensitivity by Regulating Endothelial Function in White Adipose Tissue","volume":"118","author":"Sun","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.addr.2021.114045_b0860","doi-asserted-by":"crossref","first-page":"121","DOI":"10.12688\/f1000research.10165.1","article-title":"Recent advances in understanding and treating nephrotic syndrome","volume":"6","author":"Bierzynska","year":"2017","journal-title":"F1000Res."},{"key":"10.1016\/j.addr.2021.114045_b0865","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.2337\/diabetes.54.11.3095","article-title":"The human glomerular podocyte is a novel target for insulin action","volume":"54","author":"Coward","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b0870","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cmet.2010.08.015","article-title":"Insulin signaling to the glomerular podocyte is critical for normal kidney function","volume":"12","author":"Welsh","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.addr.2021.114045_b0875","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/nm.3313","article-title":"AKT2 is essential to maintain podocyte viability and function during chronic kidney disease","volume":"19","author":"Canaud","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2021.114045_b0880","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1172\/JCI44771","article-title":"mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice","volume":"121","author":"Inoki","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2021.114045_b0885","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41467-018-08235-1","article-title":"Podocyte GSK3 is an evolutionarily conserved critical regulator of kidney function","volume":"10","author":"Hurcombe","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2021.114045_b0890","doi-asserted-by":"crossref","first-page":"15862","DOI":"10.1073\/pnas.2004651117","article-title":"A role for NPY-NPY2R signaling in albuminuric kidney disease","volume":"117","author":"Lay","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.addr.2021.114045_b0895","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3389\/fgene.2020.00993","article-title":"MicroRNAs in Podocyte Injury in Diabetic Nephropathy","volume":"11","author":"Ishii","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.addr.2021.114045_b0900","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12020-016-1069-4","article-title":"Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease","volume":"55","author":"Shao","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.addr.2021.114045_b0905","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bbrc.2016.12.145","article-title":"Repression of miR-217 protects against high glucose-induced podocyte injury and insulin resistance by restoring PTEN-mediated autophagy pathway","volume":"483","author":"Sun","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2021.114045_b0910","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2337\/diabetes.55.04.06.db05-1619","article-title":"Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes","volume":"55","author":"Nieuwdorp","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b0915","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2014040350","article-title":"Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy","volume":"26","author":"Oltean","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b0920","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.kint.2019.09.035","article-title":"Blocking matrix metalloproteinase-mediated syndecan-4 shedding restores the endothelial glycocalyx and glomerular filtration barrier function in early diabetic kidney disease","volume":"97","author":"Ramnath","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2021.114045_b0925","article-title":"The Angiogenic Effect of microRNA-21 Targeting TIMP3 through the Regulation of MMP2 and MMP9","volume":"11","author":"Hu","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.114045_b0930","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.biopha.2018.09.007","article-title":"Down-regulation of microRNA-21 reduces inflammation and podocyte apoptosis in diabetic nephropathy by relieving the repression of TIMP3 expression","volume":"108","author":"Chen","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.addr.2021.114045_b0935","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.2337\/db17-1238","article-title":"MicroRNA-129 and -335 Promote Diabetic Wound Healing by Inhibiting Sp1-Mediated MMP-9 Expression","volume":"67","author":"Wang","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b0940","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db18-0045","article-title":"VEGFC Reduces Glomerular Albumin Permeability and Protects Against Alterations in VEGF Receptor Expression in Diabetic Nephropathy","volume":"68","author":"Onions","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b0945","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2337\/diab.45.4.522","article-title":"Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice","volume":"45","author":"Sharma","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b0950","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1073\/pnas.120055097","article-title":"Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db\/db diabetic mice","volume":"97","author":"Ziyadeh","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.addr.2021.114045_b0955","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1073\/pnas.1302641110","article-title":"Primary aldosteronism and impaired natriuresis in mice underexpressing TGF\u03b21","volume":"110","author":"Kakoki","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.addr.2021.114045_b0960","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/mt.2013.235","article-title":"MicroRNA-29b inhibits diabetic nephropathy in db\/db mice","volume":"22","author":"Chen","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2021.114045_b0965","doi-asserted-by":"crossref","first-page":"11837","DOI":"10.1074\/jbc.M110.194969","article-title":"MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy","volume":"286","author":"Long","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2021.114045_b0970","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1007\/s00125-016-4021-5","article-title":"JAK inhibition in the treatment of diabetic kidney disease","volume":"59","author":"Brosius","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.addr.2021.114045_b0975","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.kint.2017.03.027","article-title":"Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice","volume":"92","author":"Zhang","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2021.114045_b0980","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.omtn.2020.10.008","article-title":"miR-150-Based RNA Interference Attenuates Tubulointerstitial Fibrosis through the SOCS1\/JAK\/STAT Pathway","volume":"22","author":"Luan","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.addr.2021.114045_b0985","doi-asserted-by":"crossref","first-page":"8142","DOI":"10.12659\/MSM.917128","article-title":"miR-34b Alleviates High Glucose-Induced Inflammation and Apoptosis in Human HK-2 Cells via IL-6R\/JAK2\/STAT3 Signaling Pathway","volume":"25","author":"Lv","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.addr.2021.114045_b0990","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mce.2016.06.004","article-title":"miR-451 suppresses the NF-kappaB-mediated proinflammatory molecules expression through inhibiting LMP7 in diabetic nephropathy","volume":"433","author":"Sun","year":"2016","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.addr.2021.114045_b0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101374","article-title":"miR-21 and miR-146a: The microRNAs of inflammaging and age-related diseases","volume":"70","author":"Olivieri","year":"2021","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.addr.2021.114045_b1000","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1681\/ASN.2015010111","article-title":"Anti-Inflammatory Role of MicroRNA-146a in the Pathogenesis of Diabetic Nephropathy","volume":"27","author":"Bhatt","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1005","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1074\/jbc.M116.753822","article-title":"Absence of miR-146a in Podocytes Increases Risk of Diabetic Glomerulopathy via Up-regulation of ErbB4 and Notch-1","volume":"292","author":"Lee","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2021.114045_b1010","doi-asserted-by":"crossref","first-page":"850","DOI":"10.2337\/db09-1342","article-title":"The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy","volume":"59","author":"Jiang","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b1015","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.biopha.2018.08.002","article-title":"Omentin-1 protects renal function of mice with type 2 diabetic nephropathy via regulating miR-27a-Nrf2\/Keap1 axis","volume":"107","author":"Song","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.addr.2021.114045_b1020","first-page":"4055","article-title":"microRNA-125b contributes to high glucose-induced reactive oxygen species generation and apoptosis in HK-2 renal tubular epithelial cells by targeting angiotensin-converting enzyme 2","volume":"20","author":"Huang","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.addr.2021.114045_b1025","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1159\/000322105","article-title":"Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy","volume":"32","author":"Fu","year":"2010","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1030","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1681\/ASN.2015091017","article-title":"Variations in MicroRNA-25 Expression Influence the Severity of Diabetic Kidney Disease","volume":"28","author":"Liu","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1035","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.bbrc.2018.09.067","article-title":"miR-423-5p suppresses high-glucose-induced podocyte injury by targeting Nox4","volume":"505","author":"Xu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2021.114045_b1040","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/ars.2017.7278","article-title":"Long Noncoding RNA LINC01619 Regulates MicroRNA-27a\/Forkhead Box Protein O1 and Endoplasmic Reticulum Stress-Mediated Podocyte Injury in Diabetic Nephropathy","volume":"29","author":"Bai","year":"2018","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.addr.2021.114045_b1045","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/jcp.29951","article-title":"Involvement of miR-27a-3p in diabetic nephropathy via affecting renal fibrosis, mitochondrial dysfunction, and endoplasmic reticulum stress","volume":"236","author":"Wu","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.addr.2021.114045_b1050","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b1055","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2337\/db14-0874","article-title":"Mitochondrial hormesis and diabetic complications","volume":"64","author":"Sharma","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b1060","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrneph.2018.9","article-title":"Mitochondrial dysfunction in diabetic kidney disease","volume":"14","author":"Forbes","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1065","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cca.2019.07.005","article-title":"Mitochondrial dysfunction in diabetic kidney disease","volume":"496","author":"Wei","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.addr.2021.114045_b1070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020220","article-title":"Pre-microRNA and mature microRNA in human mitochondria","volume":"6","author":"Barrey","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.addr.2021.114045_b1075","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s42003-020-01516-w","article-title":"miR-379 deletion ameliorates features of diabetic kidney disease by enhancing adaptive mitophagy via FIS1","volume":"4","author":"Kato","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.addr.2021.114045_b1080","doi-asserted-by":"crossref","first-page":"121ra118","DOI":"10.1126\/scitranslmed.3003205","article-title":"MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways","volume":"4","author":"Chau","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2021.114045_b1085","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nrneph.2015.177","article-title":"The emerging role of coagulation proteases in kidney disease","volume":"12","author":"Madhusudhan","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1090","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/nm1667","article-title":"Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis","volume":"13","author":"Isermann","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2021.114045_b1095","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1681\/ASN.2017030234","article-title":"Protein S Protects against Podocyte Injury in Diabetic Nephropathy","volume":"29","author":"Zhong","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1100","doi-asserted-by":"crossref","first-page":"7609","DOI":"10.1016\/j.biomaterials.2011.06.038","article-title":"The induction of epigenetic regulation of PROS1 gene in lung fibroblasts by gold nanoparticles and implications for potential lung injury","volume":"32","author":"Ng","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2021.114045_b1105","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/jth.12331","article-title":"Micro-ribonucleic Acid 494 regulation of protein S expression","volume":"11","author":"Tay","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.addr.2021.114045_b1110","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.2337\/diabetes.51.10.3090","article-title":"Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody","volume":"51","author":"Flyvbjerg","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b1115","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/diabetes.48.11.2229","article-title":"Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes","volume":"48","author":"Cooper","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b1120","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1681\/ASN.2006121304","article-title":"Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy","volume":"18","author":"Lindenmeyer","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1125","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.2337\/DB11-1655","article-title":"Vegfa protects the glomerular microvasculature in diabetes","volume":"61","author":"Sivaskandarajah","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2021.114045_b1130","doi-asserted-by":"crossref","first-page":"23457","DOI":"10.1074\/jbc.M110.136168","article-title":"Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions","volume":"285","author":"Long","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2021.114045_b1135","article-title":"Exosomal microRNA-16-5p from human urine-derived stem cells ameliorates diabetic nephropathy through protection of podocyte","author":"Duan","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.addr.2021.114045_b1140","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1055\/s-0029-1220752","article-title":"Role of growth factors in diabetic kidney disease","volume":"41","author":"Chiarelli","year":"2009","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.addr.2021.114045_b1145","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s001250051515","article-title":"Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease","volume":"43","author":"Flyvbjerg","year":"2000","journal-title":"Diabetologia"},{"key":"10.1016\/j.addr.2021.114045_b1150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/ndt\/gfh570","article-title":"Imbalance of growth factor signalling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point?","volume":"20","author":"Nieuwenhoven","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.addr.2021.114045_b1155","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3390\/jcm4081578","article-title":"MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression","volume":"4","author":"Kedmi","year":"2015","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2021.114045_b1160","doi-asserted-by":"crossref","first-page":"e140399","DOI":"10.1172\/jci.insight.140399","article-title":"Identifying cell-enriched miRNAs in kidney injury and repair","volume":"5","author":"Connor","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.addr.2021.114045_b1165","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nature04303","article-title":"Silencing of microRNAs in vivo with 'antagomirs'","volume":"438","author":"Kr\u00fctzfeldt","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.addr.2021.114045_b1170","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.786","article-title":"Silencing of microRNA families by seed-targeting tiny LNAs","volume":"43","author":"Obad","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2021.114045_b1175","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1093\/nar\/gkm024","article-title":"Specificity, duplex degradation and subcellular localization of antagomirs","volume":"35","author":"Kr\u00fctzfeldt","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2021.114045_b1180","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/gt.2014.35","article-title":"rAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: conclusion of a comparative study","volume":"21","author":"Rocca","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2021.114045_b1185","doi-asserted-by":"crossref","first-page":"14883","DOI":"10.1073\/pnas.0406421101","article-title":"Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury","volume":"101","author":"Hamar","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.addr.2021.114045_b1190","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0165-022X(90)90084-P","article-title":"Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid","volume":"20","author":"Campbell","year":"1990","journal-title":"J. Biochem. Bioph. Methods"},{"key":"10.1016\/j.addr.2021.114045_b1195","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/nar\/gkl183","article-title":"Improved targeting of miRNA with antisense oligonucleotides","volume":"34","author":"Davis","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2021.114045_b1200","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2021.114045_b1205","first-page":"562","article-title":"Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides","volume":"2","author":"Geary","year":"2001","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.addr.2021.114045_b1210","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejps.2005.04.017","article-title":"Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats","volume":"26","author":"Lendvai","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2021.114045_b1215","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1681\/ASN.2013010072","article-title":"MicroRNA-214 antagonism protects against renal fibrosis","volume":"25","author":"Denby","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1220","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1039\/c1cs15048k","article-title":"Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals","volume":"40","author":"Campbell","year":"2011","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2021.114045_b1225","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/mps4010010","article-title":"Recent Advances in miRNA Delivery Systems","volume":"4","author":"Dasgupta","year":"2021","journal-title":"Methods Protoc."},{"key":"10.1016\/j.addr.2021.114045_b1230","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1089\/hum.2019.127","article-title":"Comparison of Gene Delivery to the Kidney by Adenovirus, Adeno-Associated Virus, and Lentiviral Vectors After Intravenous and Direct Kidney Injections","volume":"30","author":"Rubin","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2021.114045_b1235","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/hum.2008.108","article-title":"Serotype chimeric and fiber-mutated adenovirus Ad5\/19p-HIT for targeting renal cancer and untargeting the liver","volume":"20","author":"Diaconu","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2021.114045_b1240","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1038\/sj.mt.6300214","article-title":"Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p","volume":"15","author":"Denby","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2021.114045_b1245","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12929-016-0223-x","article-title":"Advancement and applications of peptide phage display technology in biomedical science","volume":"23","author":"Wu","year":"2016","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.addr.2021.114045_b1250","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.biotechadv.2013.04.004","article-title":"In vivo phage display\u2013a discovery tool in molecular biomedicine","volume":"31","author":"B\u00e1b\u00ed\u010dkov\u00e1","year":"2013","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.addr.2021.114045_b1255","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nrneph.2016.156","article-title":"Nanomedicines for renal disease: current status and future applications","volume":"12","author":"Kamaly","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1260","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/mt.2010.136","article-title":"Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy","volume":"18","author":"Chen","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2021.114045_b1265","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1073\/pnas.1103573108","article-title":"Targeting kidney mesangium by nanoparticles of defined size","volume":"108","author":"Choi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.addr.2021.114045_b1270","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jconrel.2005.01.007","article-title":"Plasma membrane poration induced by ultrasound exposure: implication for drug delivery","volume":"104","author":"Mehier-Humbert","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.114045_b1275","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1681\/ASN.2010111168","article-title":"Smad3-mediated upregulation of miR-21 promotes renal fibrosis","volume":"22","author":"Zhong","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1280","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1681\/ASN.2010121308","article-title":"TGF-\u03b2\/Smad3 signaling promotes renal fibrosis by inhibiting miR-29","volume":"22","author":"Qin","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2019.07.024","article-title":"Ultrasound\/microbubble-mediated targeted delivery of anticancer microRNA-loaded nanoparticles to deep tissues in pigs","volume":"309","author":"Ianni","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2021.114045_b1290","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1681\/ASN.2014070710","article-title":"AKI Recovery Induced by Mesenchymal Stromal Cell-Derived Extracellular Vesicles Carrying MicroRNAs","volume":"26","author":"Collino","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1295","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fnins.2020.00564","article-title":"Therapeutic Effects of Transplanted Exosomes Containing miR-29b to a Rat Model of Alzheimer's Disease","volume":"14","author":"Jahangard","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.addr.2021.114045_b1300","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"Zandwijk","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2021.114045_b1305","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1172\/JCI119163","article-title":"Podocyte loss and progressive glomerular injury in type II diabetes","volume":"99","author":"Pagtalunan","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2021.114045_b1310","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/ki.2012.234","article-title":"Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy","volume":"82","author":"Weil","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2021.114045_b1315","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11892-016-0735-5","article-title":"Podocytes: the Weakest Link in Diabetic Kidney Disease?","volume":"16","author":"Lin","year":"2016","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.addr.2021.114045_b1320","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1681\/ASN.2008030312","article-title":"Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis","volume":"19","author":"Shi","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1325","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1681\/ASN.2008020233","article-title":"Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease","volume":"19","author":"Harvey","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1330","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1681\/ASN.2008020162","article-title":"Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury","volume":"19","author":"Ho","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1335","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/ki.2012.487","article-title":"Molecular fingerprinting of the podocyte reveals novel gene and protein regulatory networks","volume":"83","author":"Boerries","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2021.114045_b1340","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","article-title":"The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy","volume":"91","author":"Sockolosky","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.114045_b1345","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1002\/smll.201200733","article-title":"Kidney podocytes as specific targets for cyclo(RGDfC)-modified nanoparticles","volume":"8","author":"Pollinger","year":"2012","journal-title":"Small"},{"key":"10.1016\/j.addr.2021.114045_b1350","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA Versus miRNA as Therapeutics for Gene Silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.addr.2021.114045_b1355","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.trsl.2019.07.007","article-title":"siRNA- and miRNA-based therapeutics for liver fibrosis","volume":"214","author":"Zhao","year":"2019","journal-title":"Transl. Res."},{"key":"10.1016\/j.addr.2021.114045_b1360","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/nat.2014.0505","article-title":"siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA","volume":"25","author":"Zuckerman","year":"2015","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.addr.2021.114045_b1365","doi-asserted-by":"crossref","first-page":"14395","DOI":"10.1038\/ncomms14395","article-title":"microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism","volume":"8","author":"Hajarnis","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2021.114045_b1370","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI75852","article-title":"Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways","volume":"125","author":"Gomez","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2021.114045_b1375","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1172\/JCI135536","article-title":"p53\/microRNA-214\/ULK1 axis impairs renal tubular autophagy in diabetic kidney disease","volume":"130","author":"Ma","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2021.114045_b1380","first-page":"7","article-title":"Evaluation and optimization of chitosan derivatives-based gene delivery system via kidney epithelial cells, Adv","volume":"2","author":"Safari","year":"2012","journal-title":"Pharm. Bull."},{"key":"10.1016\/j.addr.2021.114045_b1385","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.7150\/thno.7866","article-title":"Megalin-mediated specific uptake of chitosan\/siRNA nanoparticles in mouse kidney proximal tubule epithelial cells enables AQP1 gene silencing","volume":"4","author":"Gao","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.addr.2021.114045_b1390","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201800558","article-title":"Small-Sized Cationic miRi-PCNPs Selectively Target the Kidneys for High-Efficiency Antifibrosis Treatment","volume":"7","author":"Geng","year":"2018","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2021.114045_b1395","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2021.114045_b1400","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100416","article-title":"Antisense technology: A review","volume":"296","author":"Crooke","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2021.114045_b1405","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1089\/nat.2017.0668","article-title":"The Distinct and Cooperative Roles of Toll-Like Receptor 9 and Receptor for Advanced Glycation End Products in Modulating In Vivo Inflammatory Responses to Select CpG and Non-CpG Oligonucleotides","volume":"27","author":"Paz","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.addr.2021.114045_b1410","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ymthe.2005.11.002","article-title":"Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo","volume":"13","author":"Judge","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2021.114045_b1415","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.addr.2021.114045_b1420","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/nar\/gku1343","article-title":"Sequence-dependent off-target inhibition of TLR7\/8 sensing by synthetic microRNA inhibitors","volume":"43","author":"Sarvestani","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2021.114045_b1425","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/nat.2017.0693","article-title":"The Effects of 2'-O-Methoxyethyl Oligonucleotides on Renal Function in Humans","volume":"28","author":"Crooke","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.addr.2021.114045_b1430","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/mt.2016.136","article-title":"Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers","volume":"24","author":"Crooke","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2021.114045_b1435","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/nat.2018.0723","article-title":"Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease","volume":"28","author":"Donner","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.addr.2021.114045_b1440","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.addr.2021.114045_b1445","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/cancers12071852","article-title":"A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies","volume":"12","author":"Forterre","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.addr.2021.114045_b1450","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2021.114045_b1455","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.114045_b1460","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/nar\/gkt852","article-title":"Miravirsen (SPC3649) can inhibit the biogenesis of miR-122","volume":"42","author":"Gebert","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.addr.2021.114045_b1465","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2021.114045_b1470","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ajpath.2011.04.021","article-title":"miR-21 and miR-214 are consistently modulated during renal injury in rodent models","volume":"179","author":"Denby","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.addr.2021.114045_b1475","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrneph.2012.259","article-title":"Alport syndrome\u2013insights from basic and clinical research","volume":"9","author":"Kruegel","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1480","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41573-021-00242-0","article-title":"The glomerular filtration barrier: a structural target for novel kidney therapies","volume":"20","author":"Daehn","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2021.114045_b1485","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/s41598-019-38566-y","article-title":"Anti-microRNA screen uncovers miR-17 family within miR-17\u223c92 cluster as the primary driver of kidney cyst growth","volume":"9","author":"Yheskel","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2021.114045_b1490","doi-asserted-by":"crossref","first-page":"10765","DOI":"10.1073\/pnas.1301693110","article-title":"miR-17\u223c92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease","volume":"110","author":"Patel","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.addr.2021.114045_b1495","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","article-title":"Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2021.114045_b1500","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/nat.2012.0383","article-title":"The Oligonucleotide Safety Working Group","volume":"22","author":"Schubert","year":"2012","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.addr.2021.114045_b1505","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1089\/nat.2013.0477","article-title":"Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics","volume":"24","author":"Berman","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.addr.2021.114045_b1510","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1089\/nat.2017.0671","article-title":"Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics","volume":"27","author":"Marlowe","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.addr.2021.114045_b1515","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.addr.2021.114045_b1520","first-page":"114","article-title":"How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market","volume":"30","author":"Bonneau","year":"2019","journal-title":"EJIFCC"},{"key":"10.1016\/j.addr.2021.114045_b1525","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41467-020-14349-2","article-title":"Preclinical development of a miR-132 inhibitor for heart failure treatment","volume":"11","author":"Foinquinos","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2021.114045_b1530","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","article-title":"Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study","volume":"42","author":"T\u00e4ubel","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2021.114045_b1535","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.snb.2017.06.069","article-title":"Electrochemical detection of urinary microRNAs via sulfonamide-bound antisense hybridisation","volume":"253","author":"Smith","year":"2017","journal-title":"Sens. Actuators B Chem."},{"key":"10.1016\/j.addr.2021.114045_b1540","doi-asserted-by":"crossref","first-page":"18832","DOI":"10.1039\/D0RA09874D","article-title":"Detection of urinary microRNA biomarkers using diazo sulfonamide-modified screen printed carbon electrodes","volume":"11","author":"Smith","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.addr.2021.114045_b1545","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41581-020-0286-5","article-title":"Integrated multi-omics approaches to improve classification of chronic kidney disease","volume":"16","author":"Eddy","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1550","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1681\/ASN.2018090912","article-title":"Advantages of Single-Nucleus over Single-Cell RNA Sequencing of Adult Kidney: Rare Cell Types and Novel Cell States Revealed in Fibrosis","volume":"30","author":"Wu","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1555","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1681\/ASN.2020060806","article-title":"Kidney Single-Cell Atlas Reveals Myeloid Heterogeneity in Progression and Regression of Kidney Disease","volume":"31","author":"Conway","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1560","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1681\/ASN.2020081143","article-title":"Single-Nucleus RNA Sequencing Identifies New Classes of Proximal Tubular Epithelial Cells in Kidney Fibrosis","volume":"32","author":"Lu","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1565","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1681\/ASN.2020050757","article-title":"Urinary Single-Cell Profiling Captures the Cellular Diversity of the Kidney","volume":"32","author":"Abedini","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.addr.2021.114045_b1570","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3747\/pdi.2011.00071","article-title":"A role for fibrocytes in peritoneal fibrosis?","volume":"32","author":"Bowen","year":"2012","journal-title":"Perit. Dial. Int."},{"key":"10.1016\/j.addr.2021.114045_b1575","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(16)00176-8","article-title":"The promise of personalised medicine","volume":"387","author":"Doble","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2021.114045_b1580","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41525-017-0037-0","article-title":"Prioritising the application of genomic medicine","volume":"2","author":"Doble","year":"2017","journal-title":"NPJ Genom. Med."},{"key":"10.1016\/j.addr.2021.114045_b1585","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1101\/gr.6525007","article-title":"Origin of phenotypes: genes and transcripts","volume":"17","author":"Gingeras","year":"2007","journal-title":"Genome Res."},{"key":"10.1016\/j.addr.2021.114045_b1590","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0076-6879(93)24039-W","article-title":"Detection and quantification of concerted evolution and molecular drive","volume":"224","author":"Dover","year":"1993","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2021.114045_b1595","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1101\/gr.249789.119","article-title":"Genome-wide analysis of polymerase III-transcribed Alu elements suggests cell-type-specific enhancer function","volume":"29","author":"Zhang","year":"2019","journal-title":"Genome Res."},{"key":"10.1016\/j.addr.2021.114045_b1600","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1186\/s12864-018-5292-7","article-title":"Effects of pathogenic CNVs on physical traits in participants of the UK Biobank","volume":"19","author":"Owen","year":"2018","journal-title":"BMC Genomics"},{"key":"10.1016\/j.addr.2021.114045_b1605","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.tig.2020.06.006","article-title":"The Consequences of Abnormal Gene Dosage: Lessons from Chromosome 18","volume":"36","author":"Cody","year":"2020","journal-title":"Trends Genet."},{"key":"10.1016\/j.addr.2021.114045_b1610","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41588-020-00757-z","article-title":"FinnGen, Genetics of 35 blood and urine biomarkers in the UK Biobank","volume":"53","author":"Sinnott-Armstrong","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2021.114045_b1615","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41559-019-1040-x","article-title":"Phylogenomics provides robust support for a two-domains tree of life","volume":"4","author":"Williams","year":"2020","journal-title":"Nat. Ecol. Evol."},{"key":"10.1016\/j.addr.2021.114045_b1620","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41576-020-00304-w","article-title":"Molecular and evolutionary processes generating variation in gene expression","volume":"22","author":"Hill","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2021.114045_b1625","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41576-020-00305-9","article-title":"The influence of evolutionary history on human health and disease","volume":"22","author":"Benton","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2021.114045_b1630","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/icb\/4.4.443","article-title":"Biology, Molecular and Organismic","volume":"4","author":"Dobzhansky","year":"1964","journal-title":"Am. Zool."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21004385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X21004385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:22:26Z","timestamp":1759209746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X21004385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":324,"alternative-id":["S0169409X21004385"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2021.114045","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MicroRNAs and their delivery in diabetic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2021.114045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114045"}}